- Home
- ECC vs COGT Comparison
ECC vs COGT Comparison
Compare ECC & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECC
- COGT
- Stock Information
- Founded
- ECC N/A
- COGT 2014
- Country
- ECC United States
- COGT United States
- Employees
- ECC N/A
- COGT N/A
- Industry
- ECC
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- ECC
- COGT Health Care
- Exchange
- ECC NYSE
- COGT Nasdaq
- Market Cap
- ECC 966.1M
- COGT 895.8M
- IPO Year
- ECC N/A
- COGT 2018
- Fundamental
- Price
- ECC $8.76
- COGT $8.56
- Analyst Decision
- ECC Buy
- COGT Buy
- Analyst Count
- ECC 2
- COGT 6
- Target Price
- ECC $11.00
- COGT $14.17
- AVG Volume (30 Days)
- ECC 679.0K
- COGT 1.3M
- Earning Date
- ECC 02-22-2024
- COGT 02-24-2025
- Dividend Yield
- ECC 19.16%
- COGT N/A
- EPS Growth
- ECC 369.44
- COGT N/A
- EPS
- ECC 1.69
- COGT N/A
- Revenue
- ECC $122,654,279.00
- COGT N/A
- Revenue This Year
- ECC $36.58
- COGT N/A
- Revenue Next Year
- ECC $12.88
- COGT N/A
- P/E Ratio
- ECC $5.93
- COGT N/A
- Revenue Growth
- ECC 96.41
- COGT N/A
- 52 Week Low
- ECC $8.60
- COGT $4.28
- 52 Week High
- ECC $11.79
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- ECC 37.15
- COGT 55.58
- Support Level
- ECC $8.72
- COGT $7.90
- Resistance Level
- ECC $8.88
- COGT $9.03
- Average True Range (ATR)
- ECC 0.10
- COGT 0.57
- MACD
- ECC -0.01
- COGT 0.16
- Stochastic Oscillator
- ECC 7.84
- COGT 82.72
About ECC EAGLE POINT CREDIT CO LLC
Eagle Point Credit Co Inc is an externally managed, non-diversified closed-end management investment company.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.